Centre for Molecular Processing and School of Biosciences; University of Kent; Canterbury, Kent, UK; Advanced Centre for Biochemical Engineering; Department of Biochemical Engineering; University College London; Torrington Place, London, UK.
Bioengineered. 2013 Sep-Oct;4(5):288-91. doi: 10.4161/bioe.23382. Epub 2013 Jan 17.
During the production of recombinant protein products, such as monoclonal antibodies, manufacturers must demonstrate clearance of host cell impurities and contaminants to appropriate levels prior to use in the clinic. These include host cell DNA and RNA, product related contaminants such as aggregates, and importantly host cell proteins (HCPs). Despite the importance of HCP removal, the identity and dynamics of these proteins during cell culture and downstream processing (DSP) are largely unknown. Improvements in technologies such as SELDI-TOF mass spectrometry alongside the gold standard technique of ELISA has allowed semi-quantification of the total HCPs present. However, only recently have techniques been utilized in order to identify those HCPs present and align this with the development of approaches to monitor the dynamics of HCPs during both fermentation and downstream processing. In order to enable knowledge based decisions with regards to improving HCP clearance it is vital to identify potential problematic HCPs on a cell line and product specific basis. Understanding the HCP dynamics will in the future help provide a platform to rationally manipulate and engineer and/or select suitable recombinant CHO cell lines and downstream processing steps to limit problematic HCPs.
在生产重组蛋白产品(如单克隆抗体)时,制造商必须在将其用于临床前,将宿主细胞杂质和污染物清除至适当水平。这些杂质和污染物包括宿主细胞 DNA 和 RNA、产品相关的污染物(如聚集物),以及重要的宿主细胞蛋白(HCP)。尽管 HCP 去除非常重要,但在细胞培养和下游处理(DSP)过程中,这些蛋白质的特性和动态在很大程度上是未知的。SELDI-TOF 质谱等技术的改进以及 ELISA 金标准技术的应用,使得总 HCP 含量的半定量分析成为可能。然而,直到最近,才利用这些技术来鉴定存在的 HCP,并将其与监测发酵和下游处理过程中 HCP 动态的方法的发展联系起来。为了能够基于知识做出改善 HCP 清除的决策,至关重要的是要根据细胞系和产品特异性来鉴定潜在的有问题的 HCP。了解 HCP 的动态特性将有助于为合理地操作和工程化以及/或选择合适的重组 CHO 细胞系和下游处理步骤提供一个平台,以限制有问题的 HCP。